Allogene Therapeutics (ALLO) Non Operating Income (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Non Operating Income data on file, last reported at $3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 36.15% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $16.5 million (down 3.23% YoY), and the FY2025 full-year result was $18.4 million, up 14.81% from the prior year.
• Non Operating Income slipped to $3.5 million in Q1 2026, from $3.6 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $5.9 million in Q2 2025 to a low of -$3.7 million in Q2 2022.
• A 5-year average of $2.1 million and a median of $3.5 million in 2026 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income tumbled 4050.54% in 2022 and jumped 673.06% in 2024, its largest moves.
• Tracing ALLO's Non Operating Income over 5 years: stood at -$880000.0 in 2022, then grew by 23.98% to -$669000.0 in 2023, then jumped by 248.58% to $994000.0 in 2024, then jumped by 261.57% to $3.6 million in 2025, then dropped by 3.03% to $3.5 million in 2026.
• Business Quant data shows ALLO's Non Operating Income at $3.5 million in Q1 2026, $3.6 million in Q4 2025, and $3.5 million in Q3 2025.